AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL) |
| December 06, 2020 | December 2020 Bond Updates |
|
NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA®/VENCLYXTO® (venetoclax) fixed duration treatment combinations at the virtual 62nd American Society of... |
| View more at: https://www.prnewswire.com:443/news-releases/abbvie-presents-extended-follow-up-data-for-fixed-duration-treatment-venclextavenclyxto-venetoclax-in-chronic-lymphocytic-leukemia-cll-301186833.html |
| Related News |